Emixustat is primarily used in the treatment of certain eye disorders, particularly those related to retinal diseases. It is specifically developed to address conditions like geographic atrophy, a severe form of age-related macular degeneration (AMD). The compound works by inhibiting the visual cycle, which helps reduce the accumulation of toxic byproducts in the retina that contribute to disease progression. By slowing down this cycle, Emixustat aims to preserve vision and prevent further retinal damage in patients. It is often explored as a therapeutic option to manage or delay the advancement of these chronic eye conditions.